Cancers, Vol. 11, Pages 1259: Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Cancers, Vol. 11, Pages 1259: Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis Cancers doi: 10.3390/cancers11091259 Authors: Carlo Buonerba Simona Iaccarino Pasquale Dolce Martina Pagliuca Michela Izzo Luca Scafuri Ferdinando Costabile Vittorio Riccio Dario Ribera Brigitta Mucci Simone Carrano Fernanda Picozzi Davide Bosso Luigi Formisano Roberto Bianco Sabino De Placido Giuseppe Di Lorenzo Some commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a systematic review and meta-analysis of randomized control trials (RCTs) to explore differences in outcomes associated with EGFR-TKIs among subgroups of EGFR-mutant NSCLC patients. Pooled HRs for progression or death (PFS-HRs) and pooled HRs for death (OS-HRs) were compared among sub-groups defined according to baseline clinical and demographic variables as well as type of EGFR mutation. In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12–1.56), smoking history (smokers vs. non-smokers; pooled ratio of the...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research